Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT01349361
First received: May 5, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.


Condition Intervention Phase
Photodynamic Therapy
Basal Cell Carcinomas
Procedure: Daylight mediated photodynamic therapy
Phase 2

Study Type: Interventional
Official Title: Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • complete disappearance of the BCC

Study Start Date: March 2011
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Daylight-PDT Procedure: Daylight mediated photodynamic therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • superficial BCC

Exclusion Criteria:

  • Immunosuppression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01349361

Contacts
Contact: Stine R Wiegell, MD, PhD swie0001@bbh.regionh.dk

Locations
Denmark
Bispebjerg Hospital Recruiting
Copenhagen NV, Denmark, 2400
Contact: Stine R Wiegell, MD, PhD       swie0001@bbh.regionh.dk   
Principal Investigator: Stine R Wiegell, MD, PhD         
Sponsors and Collaborators
Bispebjerg Hospital
  More Information

No publications provided

Responsible Party: Hans Christian Wulf, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT01349361     History of Changes
Other Study ID Numbers: 2010-024517-31
Study First Received: May 5, 2011
Last Updated: May 5, 2011
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Aminolevulinic Acid
Methyl 5-aminolevulinate
Dermatologic Agents
Pharmacologic Actions
Photosensitizing Agents
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014